Drug Trial Radar · NCT07815210
Phase I Trial of HHK101 in Patients With Schizophrenia
Last checked: Nov 20, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
88
Planned (sponsor's estimate)
Start
Nov 15, 2026
Primary completion
Oct 31, 2028
Study completion Oct 31, 2028
Sponsor
- Lead sponsor
- Zhuhai Huahaikang Pharmaceutical Technology Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 11, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to learn how the study drug is absorbed by the body, check for possible side effects, and see if the drug may help improve symptoms in patients with schizophrenia.
Conditions
- Schizophrenia
Interventions
HHK101-Single Dose 1Drug
A single intramuscular injection of HHK101-Dose 1
HHK101-Single Dose 2Drug
A single intramuscular injection of HHK101-Dose 2
HHK101-Single Dose 3Drug
A single intramuscular injection of HHK101-Dose 3
HHK101-Single Dose 4Drug
A single intramuscular injection of HHK101-Dose 4
HHK101-Single Dose 5Drug
A single intramuscular injection of HHK101-Dose 5
HHK101-Multiple Dose 1Drug
Three intramuscular injections of HHK101-Dose 1, every 4 weeks
HHK101-Multiple Dose 2Drug
Three intramuscular injections of HHK101-Dose 2, every 4 weeks
HHK101-Multiple Dose 3Drug
Two intramuscular injections of HHK101-Dose 3, every 8 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with Adverse eventsTime frame: Baseline through 18 weeks post-dose
- Drug ConcentrationsTime frame: Baseline through 18 weeks post-dose
- Changes from baseline in Positive and Negative Syndrome Scale (PANSS) total scoreTime frame: Baseline through 18 weeks post-dose
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Hunan Brain Hospital (The Second People's Hospital of Hunan Province)
Changsha, Hunan, China
Xi'an Mental Health Center
Xi'an, Shaanxi, China
Shanghai Mental Health Center
Shanghai, Shanghai Municipality, China
Huzhou No.3 People's Hospital
Huzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.